Innate Pharma S.A. Short Interest Plummets

Summary

Short positions in Innate Pharma S.A. (NASDAQ: IPHA) have significantly decreased by 82.5% from 376,100 shares on April 30 to 65,700 shares on May 15. The current short interest ratio is 1.9 days, with approximately 0.1% of shares being shorted. The stock is trading at $2.14, within a 12-month price range of $1.29 to $3.51. Analysts at HC Wainwright have maintained a ‘Buy’ rating but lowered the target price from $11.50 to $11.00.Market Beat

Impact Analysis

This event is classified at the company level as it pertains specifically to Innate Pharma S.A. The significant reduction in short positions suggests a shift in market sentiment towards the company, potentially indicating improved investor confidence or changes in perceived risk. The direct impact (first-order effect) includes a potential increase in share price due to reduced short selling pressure. Second-order effects could involve increased investor interest or speculative buying as perceptions improve. Opportunities for investors may include considering long positions in Innate Pharma S.A. given the maintained ‘Buy’ rating, despite the lowered target price.Market Beat